Top

Optie A:

Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
Optie B:

Deel de link per e-mail
Link delen

vorige artikel Suicidal Behavior in Juvenile Delinquents: The ...

volgende artikel Prevalence and Clinical Differences of Suicidal...

Tip

Swipe om te navigeren naar een ander artikel

03-11-2016 | Original Article | Uitgave 5/2017

Successful Treatment Response with Aripiprazole Augmentation of SSRIs in Refractory Obsessive–Compulsive Disorder in Childhood

Tijdschrift:: Child Psychiatry & Human Development > Uitgave 5/2017

Auteurs:: Ulku Akyol Ardic, Eyup Sabri Ercan, Ayse Kutlu, Deniz Yuce, Melis Ipci, Sevim Berrin Inci

» Toegang tot de volledige tekst krijgen

Abstract

The aim of this study is to evaluate the aripiprazole augmentation of selective seratonine reuptake inhibitors (SSRIs) in children and adolescents with treatment-resistant OCD. Forty-eight children and adolescents (14 girls, 34 boys), who are non-responders to treatment with at least two types of SSRIs and CBT, were administered a 12-week of augmentation. Children’s Yale-Brown Obsessive Compulsive Scale (CY-BOCS), and Clinical Global Impression-Severity and Improvement (CGI-S and CGI-I) sub-scales were used for evaluation of the treatment outcomes. The results showed that total CY-BOCS scores were decreased from 33.3 ± 7.5 to 11.7 ± 9.3 (p < 0.001), CGI-S scores decreased from 6.3 ± 0.9 to 2.7 ± 1.6 (p < 0.001), and CGI-I scores improved from 4.3 ± 0.6 to 2.2 ± 1.1 (p < 0.001). Sensitivity analyses in 29 patients without SSRI dose escalation along with aripiprazole augmentation have also revealed that improvement effect was still significant, and CY-BOCS scores were improved from 34.2 ± 7.9 to 13 ± 10.3, CGI-S improved from 6.4 ± 1.0 to 3.0 ± 1.7, and CGI-I improved from 4.4 ± 1.0 to 2.3 ± 1.1 (p < 0.001 for all). Analyses revealed that a significant clinical improvement has been observed with aripiprazole augmentation. Aripiprazole augmentation of SSRIs is a promising strategy in the management of treatment-refractory OCD children and adolescents.

Log in om toegang te krijgen

Hier inloggen

Met onderstaand(e) abonnement(en) heeft u direct toegang:

BSL Psychologie Totaal

Met BSL Psychologie Totaal blijf je als professional steeds op de hoogte van de nieuwste ontwikkelingen binnen jouw vak. Met het online abonnement heb je toegang tot een groot aantal boeken, protocollen, vaktijdschriften en e-learnings op het gebied van psychologie en psychiatrie. Zo kun je op je gemak en wanneer het jou het beste uitkomt verdiepen in jouw vakgebied.

Meer informatie

Krebs G, Heyman I (2015) Obsessive-compulsive disorder in children and adolescents. Arch Dis Child 100(5):495–499 CrossRefPubMedPubMedCentral

Eisen JL et al (2006) Impact of obsessive–compulsive disorder on quality of life. Compr Psychiatry 47(4):270–275 CrossRefPubMedPubMedCentral

Hollander E et al (2010) Quality of life outcomes in patients with obsessive–compulsive disorder: relationship to treatment response and symptom relapse. J Clin Psychiatry 71(6):784–792 CrossRefPubMed

Weidle B et al (2014) Quality of life in children with OCD with and without comorbidity. Health Qual Life Outcomes 12(1):152 CrossRefPubMedPubMedCentral

Murray CJ, Lopez AD (1997) Alternative projections of mortality and disability by cause 1990–2020: global burden of disease study. Lancet 349(9064):1498–1504 CrossRefPubMed

Flament MF et al (1988) Obsessive compulsive disorder in adolescence: an epidemiological study. J Am Acad Child Adolesc Psychiatry 27(6):764–771 CrossRefPubMed

Douglass HM et al (1995) Obsessive–compulsive disorder in a birth cohort of 18-year-olds: prevalence and predictors. J Am Acad Child Adolesc Psychiatry 34(11):1424–1431 CrossRefPubMed

Heyman I et al (2001) Prevalence of obsessive–compulsive disorder in the British nationwide survey of child mental health. Br J Psychiatry 179:324–329 CrossRefPubMed

Stewart SE et al (2004) Long-term outcome of pediatric obsessive–compulsive disorder: a meta-analysis and qualitative review of the literature. Acta Psychiatr Scand 110(1):4–13 CrossRefPubMed

10.

Micali N et al (2010) Long-term outcomes of obsessive–compulsive disorder: follow-up of 142 children and adolescents. Br J Psychiatry 197(2):128–134 CrossRefPubMed

11.

Piacentini J et al. (2003) Functional impairment in children and adolescents with obsessive–compulsive disorder. J Child Adolesc Psychopharmacol 13(Suppl 1):S61–S69 CrossRefPubMed

12.

Arumugham SS, Reddy YC (2014) Commonly asked questions in the treatment of obsessive–compulsive disorder. Expert Rev Neurother 14(2):151–163 CrossRefPubMed

13.

Bloch MH, Storch EA (2015) Assessment and management of treatment-refractory obsessive–compulsive disorder in children. J Am Acad Child Adolesc Psychiatry 54(4):251–262 CrossRefPubMedPubMedCentral

14.

Franklin ME et al (2015) Cognitive-behavioral therapy for pediatric obsessive–compulsive disorder: empirical review and clinical recommendations. Psychiatry Res 227(1):78–92 CrossRefPubMed

15.

Bridge JA et al (2007) Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. J Am Med Assoc 297(15):1683–1696 CrossRef

16.

Arumugham SS, Reddy JY (2013) Augmentation strategies in obsessive–compulsive disorder. Expert Rev Neurother 13(2):187–202 ( quiz 203) CrossRefPubMed

17.

Abudy A, Juven-Wetzler A, Zohar J (2011) Pharmacological management of treatment-resistant obsessive–compulsive disorder. CNS Drugs 25(7):585–596 CrossRefPubMed

18.

Fontenelle LF et al (2007) An update on the pharmacological treatment of obsessive–compulsive disorder. Expert Opin Pharmacother 8(5):563–583 CrossRefPubMed

19.

Skapinakis P, Papatheodorou T, Mavreas V (2007) Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive–compulsive disorder: a meta-analysis of the randomized controlled trials. Eur Neuropsychopharmacol 17(2):79–93 CrossRefPubMed

20.

DeLeon A, Patel NC, Crismon ML (2004) Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 26(5):649–666 CrossRefPubMed

21.

Matsunaga H et al (2011) A case series of aripiprazole augmentation of selective serotonin reuptake inhibitors in treatment-refractory obsessive compulsive disorder. Int J Psychiatry Clin Pract 15(4):263–269 CrossRefPubMed

22.

Higuma H et al (2012) Aripiprazole augmentation in 13 patients with refractory obsessive–compulsive disorder: a case series. World J Biol Psychiatry 13(1):14–21 CrossRefPubMed

23.

Muscatello MR et al (2011) Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive–compulsive disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol 31(2):174–179 CrossRefPubMed

24.

Sayyah M et al (2012) Effects of aripiprazole augmentation in treatment-resistant obsessive–compulsive disorder (a double blind clinical trial). Depress Anxiety 29(10):850–854 CrossRefPubMed

25.

Masi G et al (2010) Aripiprazole augmentation in 39 adolescents with medication-resistant obsessive–compulsive disorder. J Clin Psychopharmacol 30(6):688–693 CrossRefPubMed

26.

Ercan ES et al (2015) A promising preliminary study of aripiprazole for treatment-resistant childhood obsessive–compulsive disorder. J Child Adolesc Psychopharmacol 25(7):580–584 CrossRefPubMed

27.

APA (2000) Diagnostic and statistical manual of mental disorders, 4th edn, text revision. American Psychiatric Association, Washington

28.

Gökler B et al (2004) Reliability and validity of schedule for affective disorders and schizophrenia for school age children-present and lifetime version-Turkish version (K-SADS-PL-T). Turk J Child Adolesc Health 11(3):109–116

29.

Scahill L et al (1997) Children’s Yale-Brown obsessive compulsive scale: reliability and validity. J Am Acad Child Adolesc Psychiatry 36(6):844–852 CrossRefPubMed

30.

Yucelen AG et al (2006) Interrater reliability and clinical efficacy of Children’s Yale-Brown obsessive–compulsive scale in an outpatient setting. Compr Psychiatry 47(1):48–53 CrossRefPubMed

31.

Guy W (1976) ECDEU assessment manual for psychopharmacology. US Department of Heath, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration, Rockville

32.

Bollini P et al (1999) Effectiveness of antidepressants. Meta-analysis of dose–effect relationships in randomised clinical trials. Br J Psychiatry 174:297–303 CrossRefPubMed

33.

National Institute for Health and Clinical Excellence: guidance. Obsessive–compulsive disorder: core interventions in the treatment of obsessive–compulsive disorder and body dysmorphic disorder, 2006.

34.

Fonseka TM, Muller DJ, Kennedy SH (2016) Inflammatory cytokines and antipsychotic-induced weight gain: review and clinical implications. Mol Neuropsychiatry 2(1):1–14 CrossRefPubMedPubMedCentral

35.

Findling RL et al (2009) Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 70(10):1441–1451 CrossRefPubMed

36.

Bobo WV et al (2013) Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. J Am Med Assoc Psychiatry 70(10):1067–1075

37.

Hirsch LE, Pringsheim T (2016) Aripiprazole for autism spectrum disorders (ASD). Cochrane Database Syst Rev 6:CD009043

38.

Connor KM et al (2005) The use of aripiprazole in obsessive–compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry 66(1):49–51 CrossRefPubMed

39.

Storch EA et al (2008) Aripiprazole augmentation of incomplete treatment response in an adolescent male with obsessive–compulsive disorder. Depress Anxiety 25(2):172–174 CrossRefPubMed

40.

Sarkar R, Klein J, Kruger S (2008) Aripiprazole augmentation in treatment-refractory obsessive–compulsive disorder. Psychopharmacology (Berl) 197(4):687–688 CrossRef

Titel: Successful Treatment Response with Aripiprazole Augmentation of SSRIs in Refractory Obsessive–Compulsive Disorder in Childhood
Auteurs:: Ulku Akyol Ardic
Eyup Sabri Ercan
Ayse Kutlu
Deniz Yuce
Melis Ipci
Sevim Berrin Inci
Publicatiedatum: 03-11-2016
DOI: https://doi.org/10.1007/s10578-016-0694-8
Uitgeverij: Springer US
Tijdschrift: Child Psychiatry & Human Development
Uitgave 5/2017
Print ISSN: 0009-398X
Elektronisch ISSN: 1573-3327

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Tip

Swipe om te navigeren naar een ander artikel

Successful Treatment Response with Aripiprazole Augmentation of SSRIs in Refractory Obsessive–Compulsive Disorder in Childhood

Abstract

Log in om toegang te krijgen

Met onderstaand(e) abonnement(en) heeft u direct toegang:

BSL Psychologie Totaal

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Tip

Swipe om te navigeren naar een ander artikel

Abstract

Log in om toegang te krijgen

Met onderstaand(e) abonnement(en) heeft u direct toegang:

BSL Psychologie Totaal

Andere artikelen Uitgave 5/2017

Assessing Clinical Improvement in School-Based Treatment for Social Anxiety Disorder: Agreement Between Adolescents, Parents, and Independent Evaluators

Family Relations and Psychopathology: Examining Depressive and Bulimic Symptomatology

Aripiprazole in the Treatment of Irritability in Children and Adolescents with Autism Spectrum Disorder in Japan: A Randomized, Double-blind, Placebo-controlled Study

Prevalence and Clinical Differences of Suicidal Thoughts and Behaviors in a Community Sample of Youth Receiving Cognitive-Behavioral Therapy for Anxiety

Direct and Indirect Effects of Maltreatment and Social Support on Children’s Social Competence Across Reporters

Predictors of Program Use and Child and Parent Outcomes of A Brief Online Parenting Intervention